Guardian Pharmacy Services, Inc. (GRDN)
| Market Cap | 2.61B +74.2% |
| Revenue (ttm) | 1.46B +10.3% |
| Net Income | 65.91M |
| EPS | 1.04 |
| Shares Out | 63.34M |
| PE Ratio | 39.86 |
| Forward PE | 30.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 397,508 |
| Open | 41.43 |
| Previous Close | 41.60 |
| Day's Range | 40.67 - 41.48 |
| 52-Week Range | 23.14 - 48.33 |
| Beta | 0.02 |
| Analysts | Strong Buy |
| Price Target | 49.86 (+20.79%) |
| Est. Earnings | Nov 9, 2026 |
About GRDN
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company’s individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for GRDN stock is "Strong Buy." The 12-month stock price target is $49.86, which is an increase of 20.79% from the latest price.
News
Guardian Pharmacy initiated with an Overweight at KeyBanc
KeyBanc initiated coverage of Guardian Pharmacy (GRDN) with an Overweight rating and $52 price target
KeyBanc starts ‘definitive leader’ Guardian Pharmacy at Overweight
KeyBanc initiated coverage of Guardian Pharmacy (GRDN) with an Overweight rating and $52 price target The firm views Guardian as the “definitive leader” in long-term care pharmacy with structural adva...
Guardian Pharmacy price target raised to $51 from $47 at Truist
Truist raised the firm’s price target on Guardian Pharmacy (GRDN) to $51 from $47 and keeps a Buy rating on the shares as part of a broader research note updating…
Guardian Pharmacy Services Transcript: 2026 Jefferies Healthcare Services and Technology Conference
The company leverages a unique local autonomy model and strong financial position to drive growth through organic expansion, acquisitions, and greenfield startups. Despite IRA-related revenue headwinds, margins remain stable, and recent strategic moves, including a file buy acquisition and geographic expansion, position the business for continued success.
Guardian Pharmacy acquires assets of Nautilus Pharmacy, terms not disclosed
Guardian Pharmacy (GRDN) Services announced the acquisition of assets from Tennessee-based Nautilus Pharmacy, including prescription files, related pharmacy inventory, and certain fixed assets. “Guard...
Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) has acquired assets from Tennessee-based Nautilus Pharmacy.
Guardian Pharmacy Services, Inc., to Participate in Upcoming Jefferies Healthcare Services Investor Conference
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that it will participate in the Jefferies Healthcare Services Conference, on Tuesday, September 15, 2026. Fred B...
Guardian Pharmacy price target raised to $49 from $43 at Oppenheimer
Oppenheimer raised the firm’s price target on Guardian Pharmacy (GRDN) to $49 from $43 and keeps an Outperform rating on the shares after the company reported earnings. The firm notes…
Guardian Pharmacy Services Earnings Call Transcript: Q2 2026
Revenue grew 2% year-over-year in Q2 2026, with adjusted EBITDA up 19% and net income reaching $22.1 million. Full-year guidance was raised, reflecting strong organic growth and disciplined M&A, while IRA-related pricing reductions continue to impact reported revenue.
Guardian Pharmacy Services Quarterly report: Q2 2026
Guardian Pharmacy Services has published its Q2 2026 quarterly earnings report on August 6, 2026.
Guardian Pharmacy Services Earnings release: Q2 2026
Guardian Pharmacy Services released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financial results for the s...
Guardian Pharmacy Services, Inc. to Report Second Quarter 2026 Financial Results and Host Conference Call
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that it will release second quarter 2026 financial results after market close on Thursday, August 6, 2026. Manag...
Guardian Pharmacy acquires Wellness Concepts, terms not disclosed
Guardian Pharmacy (GRDN) Services announced the acquisition of Wellness Concepts, an LTC pharmacy based in Grottoes, Va. This addition expands Guardian’s footprint in Virginia to three pharmacies in G...
Guardian Pharmacy Services Expands Virginia Footprint With Acquisition of Wellness Concepts
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) has acquired Wellness Concepts, a long-term care pharmacy based in Grottoes, Virginia.
Guardian Pharmacy names Will Mudd CFO, David Morris COO
Guardian Pharmacy (GRDN) Services announced that Kendall Forbes, who has served as Executive Vice President of Sales & Operations since 2004, has decided to retire, effective as of July 1.
Guardian Pharmacy Services, Inc. Announces Leadership Transitions
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that Kendall Forbes, who has served as Executive Vice President of Sales & Operations since 2004, has decided to...
Guardian Pharmacy price target raised to $47 from $43 at Truist
Truist raised the firm’s price target on Guardian Pharmacy (GRDN) to $47 from $43 and keeps a Buy rating on the shares. The firm remains bullish on Guardian following a…
Guardian Pharmacy price target raised to $47 from $42 at BofA
BofA analyst Allen Lutz raised the firm’s price target on Guardian Pharmacy (GRDN) to $47 from $42 and keeps a Buy rating on the shares. After having hosted a pharmacy…
Guardian Pharmacy Services Transcript: Bank of America Global Healthcare Conference 2026
Delivered a strong quarter, raised annual guidance, and expects high single-digit organic growth, with additional upside from M&A. Maintains a strong balance sheet, leverages scale for profitability, and sees significant opportunity for expansion in the fragmented assisted living pharmacy market.
Guardian Pharmacy Services Slides: Investor presentation
Guardian Pharmacy Services has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Guardian Pharmacy price target raised to $43 from $38 at Oppenheimer
Oppenheimer raised the firm’s price target on Guardian Pharmacy (GRDN) to $43 from $38 and keeps an Outperform rating on the shares following the company’s earnings report. Overall, the results…
Guardian Pharmacy files automatic Class A common stock offering
16:45 EDT Guardian Pharmacy (GRDN) files automatic Class A common stock offering
Guardian Pharmacy affirms FY26 revenue view of $1.40B-$1.42B, consensus $1.42B
16:54 EDT Guardian Pharmacy (GRDN) affirms FY26 revenue view of $1.40B-$1.42B, consensus $1.42B
Guardian Pharmacy Services Earnings Call Transcript: Q1 2026
Solid Q1 results with 2% revenue growth and 19% gross profit increase despite IRA headwinds. Updated adjusted EBITDA guidance to $123–$127 million, maintained revenue outlook, and continued robust M&A activity.